• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 04, 2018 at 10:52: PM
via Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual meeting, it rolled out data to support that notion.

article source
 




Top Bottom
Back
Quote